Whether you are a manufacturer or user of chemical substances, Equitox guides you through your REACh regulatory compliance process. Based on the assessment of your obligations, we define the best strategy for your products.
I wish to be in compliance with REACh…
…and I need assistance in the preparation of the technical registration dossier
- Searches for and analyses existing data, and submits Inquiries to ECHA,
- Determines the registration strategy,
- Makes exemption requests for product and process-oriented research and development (PPORD),
- Sets out a data acquisition strategy,
- Generates missing data,
- Creates the IUCLID dossier and the Chemical Safety Report (CSR).
…and I would like someone to deal with the administrative part of the registration process for me
- Represents you within SIEFs and consortia,
- Ensures compliance with data sharing rules and the cost of the letter of access.
- Manages your REACh-IT account.
…and I would like to update dossiers already registered
- Identifies compliance deviations
- Assists with substance identification issues,
- Verifies the strictly controlled conditions (SCC) of intermediates,
- Updates your dossiers with more relevant data to make sure ECHA does not prioritise your substances.
What happens to my dossier once it has been registered?
What should I do if my dossier is evaluated?
- Explains ECHA’s requests to you,
- Supports you during consultation stages to bring forward admissible arguments likely to challenge the Authorities’ requirements,
- Helps ensure the compliance of your dossier, based on its in-depth knowledge of guidance documents and its technical expertise.
What should I do if my substance is evaluated?
- Puts in place an alert on priority substances in your company or on your strategic raw materials, which will be evaluated in the coming years,
- Informs you of issues targeted by the authorities (e.g. PBT, Endocrine Disruptor, etc.) ,
- Helps you answer the questions asked. To do this, Equitox develops all its arguments and expertise to minimise resultant costs.
What should I do in the event of a restriction (project)?
- Analyses the impact of this restriction on your markets or raw materials,
- Explores a range of possible options: production shutdown, development of a substitute product, shifts in the production chain, etc.
What should I do if my substance falls under the authorisation process?
- Identifies in advance potential future substances of very high concern (SVHC),
- Monitors changes to the candidate list and explains the resulting obligations,
- Informs you of ECHA prioritisation, substances included in annexe XIV and the consequences for your markets,
- Contributes to the preparation of your authorisation dossiers.
I would like assistance in preparing my extended SDSs
- Audits your SDSs,
- Drafts annexes to SDSs.
I would like to know whether my use complies with my supplier’s eSDS
- Analyses your conditions of use and compares them with those indicated in the exposure scenarios featured in your supplier’s SDS,
- Facilitates exchanges with your suppliers if deviations are identified,
- Outlines possible alternatives in case of non-compliance with the eSDS,
- Draws up the chemical safety report (DU-CSR) taking into account your conditions of use.
I would like assistance in my dealings with national authorities or ECHA
- is involved in interactions with the authorities (written communications and meetings),
- Queries help desks in a totally confidential manner,
- Submits notifications to ECHA (authorised use for substance included in Annexe XIV, Candidate list substance in article, use not supported by supplier, different classification).
I would like to be informed of regulatory developments and anticipate future changes
- Regularly monitors developments specific to your situation, products and markets,
- Anticipates future regulatory developments (Polymers, PMT),
- Analyses major alerts which may concern your products (classification, restriction, SVHC),
- Analyses regulatory positioning for your R&D projects.
I would like to conduct a Due Diligence review
- Audits the product portfolio prior to an acquisition or merger, with a view to clearly mapping out the regulatory status of substances,
- Anticipates possible restrictions or prohibitions which could affect products in the near future.